文献速递肾癌与肾肿瘤

立体定向放疗联合靶向或免疫治疗用于转移性肾细胞癌

Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
PubMed 文献 · BJU Int · 2020-11-19

1年总生存率、局部控制率和无进展生存率分别为71%、75%和25%,未观察到4级或5级毒性,寡转移性疾病(OMD)是OS和PFS的独立预后因素。

要点

  • SRT同步TT或ICI治疗mRCC安全,未增加严重毒性信号。
  • 1年OS、LC和PFS率分别为71%、75%和25%。
  • OMD是OS和PFS的独立预后因素,应优先考虑局部治疗。

核心结论

  • TT或免疫治疗同步SRT治疗mRCC安全,无严重毒性增加信号。
  • OMD和良好ECOG-PS患者预后较好,应作为前瞻性试验基础。

研究设计与样本

  • SRT同步(≤30天)TT或ICI治疗,分析OS、PFS、LC及系统治疗切换时间。

主要发现

  • 1年OS、LC和PFS率分别为71%、75%和25%。
  • TT与ICI组中位OS和PFS无显著差异(P=0.329)。
  • 1年后62%患者维持原系统治疗,ICI组维持率高于TT组(83% vs 36%;P=0.035)。
  • OMD是OS(P=0.004,95%CI 0.035-0.528)和PFS(P=0.004,95%CI 0.165-0.717)独立预后因素。
  • ECOG-PS是OS的另一独立预后因素(P=0.001,95%CI 0.001-0.351)。

关键数值与推荐

  • 急性3级毒性2例,晚期3级毒性1例,无4级或5级毒性。
  • 中位SRT剂量65 Gy(范围40-129.4 Gy,生物有效剂量)。
  • 46%患者对新发病灶重复放疗。

临床怎么用

  • 对接受TT或ICI的mRCC患者,可考虑全剂量SRT以实现最佳转移灶控制。
  • OMD且ECOG-PS良好的患者可能从同步SRT中获益。

局限性

  • 缺乏对照组,无法直接比较同步治疗与序贯治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT) in patients with metastatic renal cell carcinoma (mRCC) concurrently receiving targeted therapy (TT) or immunotherapy. PATIENTS AND METHODS: Data on patients with mRCC were extracted from a retrospective international multicentre register study (TOaSTT), investigating SRT concurrent (≤30 days) with TT/immune checkpoint inhibitor (ICI) therapy. Overall survival (OS), progression-free survival (PFS), local metastasis control (LC) and time to systemic therapy switch were analysed using Kaplan-Meier curves and log-rank testing. Clinical and treatment factors influencing survival were analysed using multivariate Cox regression. Acute and late SRT-induced toxicity were defined according to the Common Terminology Criteria for Adverse Events v.4.03. RESULTS: Fifty-three patients who underwent 128 sessions of SRT were included, of whom 58% presented with oligometastatic disease (OMD). ICIs and TT were received by 32% and 68% of patients, respectively. Twenty patients (37%) paused TT for a median (range) of 14 (2-21) days. ICI therapy was not paused in any patient. A median (range) of 1 (1-5) metastatic tumour was treated per patient, with a median (range) SRT dose of 65 (40-129.4) Gy (biologically effective dose). The OS, LC and PFS rates at 1 year were 71%, 75% and 25%, respectively. The median OS and PFS were not significantly different among patients receiving TT vs those receiving ICIs (P = 0.329). New lesions were treated with a repeat radiotherapy course in 46% of patients. After 1 year, 62% of patients remained on the same systemic therapy as at the time of SRT; this was more frequent for ICI therapy compared to TT (83% vs 36%; P = 0.035). OMD was an independent prognostic factor for OS (P = 0.004, 95% confidence interval [CI] 0.035-0.528) and PFS (P = 0.004; 95% CI 0.165-0.717) in multivariate analysis. Eastern Cooperative Oncology Group performance status (ECOG-PS) was the other independent prognostic factor for OS (P = 0.001, 95% CI 0.001-0.351). Acute grade 3 toxicity was observed in two patients, and late grade 3 toxicity in one patient. No grade 4 or 5 toxicity was observed. CONCLUSION: Combined treatment with TT or immunotherapy and concurrent SRT was safe, without signals of increased severe toxicity. As we observed no signal of excess toxicity, full-dose SRT should be considered to achieve optimal metastasis control in patients receiving TT or immunotherapy. Favourable PFS and OS were observed for patients with oligometastatic RCC with a good ECOG-PS, which should form the basis for prospective testing of this treatment strategy in properly designed clinical trials.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Kroeze SGC, Fritz C, Schaule J, et al. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int. 2020. PMID: 33113260. doi:10.1111/bju.15284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。